EUVIMEDEUVIMED entdecken
Crossref

Mechanistic study of quercetin in the treatment of hepatocellular carcinoma with diabetes via MEK/ERK pathway

Feng Lin, Weiguo Zhou, Xiao Yuan, Siyu Liu, Zhipeng He

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.113194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Feng Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China; Anhui Public Health Clinical Center, H…. Hauptthemen laut MEDLINE: Quercetin, Carcinoma, Hepatocellular, Liver Neoplasms, MAP Kinase Signaling System. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 66 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a complex disease, further exacerbated by coexisting diabetes. With the rising incidence of HCC-diabetes cases, alternative treatment strategies are urgently needed. Traditional Chinese Medicine (TCM) offers promising options, and quercetin, a bioactive flavonoid, has shown significant antitumor and antidiabetic effects. This study aimed to investigate the efficacy of quercetin in treating HCC with diabetes using bioinformatics and network pharmacology. We constructed a prognostic model for HCC-diabetes using multivariate Cox proportional hazards regression and identified potential targets for quercetin by intersecting quercetin target genes with HCC-diabetes genes. Molecular docking and molecular dynamics simulations screened these potential targets, and in vitro experiments verified quercetin's targets and pathways. The results revealed a prediction model with four essential genes that effectively predict HCC prognosis in diabetic patients. IL6 and MMP9 were identified as potential targets of quercetin through molecular docking and dynamics simulations. In vitro experiments revealed that quercetin promotes apoptosis, inhibits cell proliferation, and suppresses epithelial-mesenchymal transition (EMT) in HepG2 cells under high-glucose conditions by reducing IL6 expression and inhibiting the MEK/ERK pathway. In summary, quercetin may delay the progression of HCC-diabetes by modulating IL6 to inhibit the MEK/ERK signaling pathway, thereby promoting apoptosis and inhibiting the proliferation and EMT of HepG2 cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuercetinCarcinoma, HepatocellularLiver NeoplasmsMAP Kinase Signaling SystemMolecular Docking SimulationApoptosisHumansHep G2 CellsInterleukin-6Cell ProliferationEpithelial-Mesenchymal TransitionMatrix Metalloproteinase 9Diabetes MellitusHypoglycemic Agents

Stichwörter der Autor:innen

BioinformaticsDiabetesHepatocellular carcinomaMolecular dockingMolecular dynamics simulationNetwork pharmacologyQuercetin

Substanzen

QuercetinInterleukin-6Matrix Metalloproteinase 9IL6 protein, humanMMP9 protein, humanHypoglycemic Agents

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China; Anhui Public Health Clinical Center, Hefei 230032, China.
  • Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
  • Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China. Electronic address: Liu_siyu2019@163.com.
  • Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China; Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University,…

Zitieren

APA

Lin, F., Zhou, W., Yuan, X., Liu, S., & He, Z. (2024). Mechanistic study of quercetin in the treatment of hepatocellular carcinoma with diabetes via MEK/ERK pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113194

Vancouver

Lin F, Zhou W, Yuan X, Liu S, He Z. Mechanistic study of quercetin in the treatment of hepatocellular carcinoma with diabetes via MEK/ERK pathway. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113194

BibTeX
@article{Lin2024,
  author = {Lin, Feng and Zhou, Weiguo and Yuan, Xiao and Liu, Siyu and He, Zhipeng},
  title = {Mechanistic study of quercetin in the treatment of hepatocellular carcinoma with diabetes via MEK/ERK pathway},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.113194}
}
Kostenlos starten →